Judit Cubedo, CEO of GlyCardial, finalist for the EU Prize for Women Innovators 2020 Blog Post

Judit Cubedo, co-founder and CEO of GlyCardial Diagnostics, is one of the twenty-one women selected as finalists for the EU Prize for Women Innovators 2020, an award given annually to the most talented and inspiring entrepreneurs in Europe. The company led by Judit, which is based in the Barcelona Science Park, is conducting a clinical trial to validate the performance of Apo J-Glyc as a novel biomarker for the early detection of Myocardial Ischaemia. The award winners will be announced at the European Research and Innovation Days taking place on 22-24 September 2020.

 

Launch of the company Gate2Brain, based on novel technology developed at IRB Barcelona to transport drugs into the brain Blog Post

The Institute for Research in Biomedicine (IRB Barcelona), the University of Barcelona (UB) and the Sant Joan de Déu Research Institute (IRSJD)- Hospital Sant Joan de Déu (SJD) have set up Gate2Brain, a company based on a novel technology to transport drugs into the brain. The biotech, based in the Barcelona Science Park, is the second joint spin-off between IRB Barcelona and the UB to be funded by the Mind the Gap Programme run by the Botín Foundation.

 

Gorka Etxebarria, new Chief Scientific Officer of Nostrum Biodiscovery Blog Post

Nostrum Biodiscovery (NBD) has appointed Dr. Gorka Etxebarria as new Chief Scientific Officer. Dr Etxebarria has a solid career linked to drug discovery projects in the pharmaceutical industry. His incorporation comes after the signing of Ezequiel Mas as new company CEO, to pilot a new stage of growth as a global provider of leading molecular simulation technologies applied to drug discovery and design.

 

The European Union has granted the coordination of three European projects to IBEC Blog Post

The European Union has granted the coordination of three European projects to the Institute for Bioengineering of Catalonia (IBEC) to continue combining medicine, science and technology with the aim of improving people’s health. Among the milestones achieved in recent years by the experts of the Institute, based at the Barcelona Science Park, we can find the development of bioimplants enriched with stem cells or the generation of vascularized mini-kidneys that have helped identify a drug in clinical phase that blocks the effects of SARS-Co-V2.

 

Scientists at CNAG-CRG and CRG develop a new tool to film genome dynamics Blog Post

Scientists from the Centro Nacional de Análisis Genómico (CNAG-CRG) –based in the Barcelona Science Park and integrated into the Centre for Genomic Regulation (CRG)– have developed TADdyn, a tool that can generate movies of how genomes change over time. The finding, published in Nature Communications, will help researchers worldwide learn much more about the direct relationship between structure and function in the genome.

 

EIT Health selects Droplite, Ninevah and Oxolife for Headstart program Blog Post

Droplite, Ninevah Therapeutics and Oxolife, presents at the Barcelona Science Park, are three of the 16 Spanish startups that will participate in Headstart, the program of the European Institute of Innovation and Technology in Health (EIT Health) that offers support and financing of up to 50,000 € because emerging companies develop their innovations within a unique ecosystem, which gives them access to financing, experts, contacts and knowledge.

 

GalChimia renews the Crédit d’Impôt Recherche (CIR) accreditation Blog Post

GalChimia has renewed the Crédit d’Impôt Recherche (CIR) accreditation from the French Government, which certifies the company as a provider of R&D services in France. The evaluation is related to the company’s participation in the SHIKIFACTORY100 European project, aimed at the production of compounds of high added value in the chemical, food and cosmetic industries. The Galician company has doubled the surface and staff of its R&D&I center at the Barcelona Science Park, which was opened two years ago to accelerate its growth and internationalization strategy.